25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

IDXG (Interpace) Stock Analysis
Buy, Hold or Sell?

Let's analyze Interpace together

I guess you are interested in Interpace Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Interpace’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Interpace’s Price Targets

I'm going to help you getting a better view of Interpace Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Interpace Biosciences Inc

I send you an email if I find something interesting about Interpace Biosciences Inc.

1. Quick Overview

1.1. Quick analysis of Interpace (30 sec.)










1.2. What can you expect buying and holding a share of Interpace? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.13
Expected worth in 1 year
$13.59
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$13.72
Return On Investment
1,781.7%

For what price can you sell your share?

Current Price per Share
$0.77
Expected price per share
$0.7 - $0.92
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Interpace (5 min.)




Live pricePrice per Share (EOD)
$0.77
Intrinsic Value Per Share
$1.29 - $15.70
Total Value Per Share
$1.16 - $15.57

2.2. Growth of Interpace (5 min.)




Is Interpace growing?

Current yearPrevious yearGrowGrow %
How rich?-$582k-$60.3m$30.5m102.1%

How much money is Interpace making?

Current yearPrevious yearGrowGrow %
Making money$1.9m$289.7k$1.6m85.3%
Net Profit Margin16.3%2.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Interpace (5 min.)




2.4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Interpace?

Welcome investor! Interpace's management wants to use your money to grow the business. In return you get a share of Interpace.

First you should know what it really means to hold a share of Interpace. And how you can make/lose money.

Speculation

The Price per Share of Interpace is $0.7699. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Interpace.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Interpace, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.13. Based on the TTM, the Book Value Change Per Share is $3.43 per quarter. Based on the YOY, the Book Value Change Per Share is $0.08 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Interpace.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.3748.4%0.4557.9%0.078.5%-0.20-25.7%-0.52-67.3%-0.40-52.0%
Usd Book Value Change Per Share0.3748.1%3.43445.4%0.0810.3%-0.05-6.8%-0.41-53.3%-0.03-3.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.3748.1%3.43445.4%0.0810.3%-0.05-6.8%-0.41-53.3%-0.03-3.8%
Usd Price Per Share0.94-1.65-1.16-1.58-3.30-2.33-
Price to Earnings Ratio0.63-0.96-2.23-1.49-0.20--0.41-
Price-to-Total Gains Ratio2.54-2.77-1.34-1.79--1.89--6.71-
Price to Book Ratio-7.14--3.19--0.08--1.14-0.82-0.91-
Price-to-Total Gains Ratio2.54-2.77-1.34-1.79--1.89--6.71-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.7699
Number of shares1298
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share3.43-0.41
Usd Total Gains Per Share3.43-0.41
Gains per Quarter (1298 shares)4,451.23-532.43
Gains per Year (1298 shares)17,804.93-2,129.70
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1017805177950-2130-2140
2035610356000-4259-4270
3053415534050-6389-6400
4071220712100-8519-8530
5089025890150-10649-10660
601068301068200-12778-12790
701246351246250-14908-14920
801424391424300-17038-17050
901602441602350-19167-19180
1001780491780400-21297-21310

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%8.04.00.066.7%8.012.00.040.0%11.029.00.027.5%33.047.021.032.7%
Book Value Change Per Share4.00.00.0100.0%7.05.00.058.3%7.012.01.035.0%13.026.01.032.5%39.061.01.038.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%3.00.098.03.0%
Total Gains per Share4.00.00.0100.0%7.05.00.058.3%7.012.01.035.0%13.026.01.032.5%39.061.01.038.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Interpace Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.3713.429-89%0.079+368%-0.052+114%-0.410+211%-0.029+108%
Book Value Per Share---0.132-6.767+5043%-13.679+10296%-11.254+8453%-5.411+4012%-1.873+1323%
Current Ratio--1.3430.895+50%0.823+63%0.841+60%0.872+54%1.163+15%
Debt To Asset Ratio--1.0403.212-68%5.393-81%4.307-76%2.864-64%1.705-39%
Debt To Equity Ratio----0%-0%-0%1.446-100%2.101-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value---10918292.580-36677734.345+236%-69154790.500+533%-58901527.198+439%-35683387.994+227%-20237870.959+85%
Eps--0.3720.446-17%0.066+467%-0.198+153%-0.518+239%-0.400+208%
Ev To Sales Ratio---0.237-0.757+219%-1.714+623%-1.489+528%-0.901+280%-0.493+108%
Free Cash Flow Per Share--0.2790.288-3%0.123+128%0.030+836%-0.195+170%-0.261+193%
Free Cash Flow To Equity Per Share---0.060-0.091+53%-0.179+199%-0.174+190%-0.263+338%-0.092+54%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--15.704----------
Intrinsic Value_10Y_min--1.294----------
Intrinsic Value_1Y_max--0.330----------
Intrinsic Value_1Y_min---0.850----------
Intrinsic Value_3Y_max--1.940----------
Intrinsic Value_3Y_min---1.720----------
Intrinsic Value_5Y_max--4.692----------
Intrinsic Value_5Y_min---1.670----------
Market Cap3399031.510-22%4157707.4207273265.655-43%5099209.500-18%6982806.135-40%14583462.006-71%17892879.041-77%
Net Profit Margin--0.1430.163-12%0.026+448%-0.129+190%-0.288+301%-0.483+438%
Operating Margin----0%0.019-100%-0.0110%-0.2080%-0.3120%
Operating Ratio--1.2011.164+3%1.327-9%1.353-11%1.500-20%1.546-22%
Pb Ratio-5.851+18%-7.144-3.185-55%-0.085-99%-1.142-84%0.825-966%0.912-883%
Pe Ratio0.517-22%0.6310.957-34%2.231-72%1.491-58%0.200+215%-0.413+165%
Price Per Share0.770-22%0.9401.647-43%1.155-19%1.582-41%3.303-72%2.328-60%
Price To Free Cash Flow Ratio0.689-22%0.8421.491-44%-3.230+484%-0.854+201%-2.648+415%-2.196+361%
Price To Total Gains Ratio2.078-22%2.5372.766-8%1.339+89%1.790+42%-1.892+175%-6.712+365%
Quick Ratio--1.0100.632+60%0.377+168%0.450+124%0.535+89%0.901+12%
Return On Assets--0.1140.140-19%0.024+383%-0.039+134%-0.061+154%-0.061+154%
Return On Equity----0%-0%-0%-0.1190%-0.1190%
Total Gains Per Share--0.3713.429-89%0.079+368%-0.052+114%-0.410+211%-0.029+108%
Usd Book Value---582000.000-29876750.000+5033%-60391500.000+10277%-49685666.667+8437%-23887850.000+4004%398050.000-246%
Usd Book Value Change Per Share--0.3713.429-89%0.079+368%-0.052+114%-0.410+211%-0.029+108%
Usd Book Value Per Share---0.132-6.767+5043%-13.679+10296%-11.254+8453%-5.411+4012%-1.873+1323%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value---10918292.580-36677734.345+236%-69154790.500+533%-58901527.198+439%-35683387.994+227%-20237870.959+85%
Usd Eps--0.3720.446-17%0.066+467%-0.198+153%-0.518+239%-0.400+208%
Usd Free Cash Flow--1235000.0001272750.000-3%541250.000+128%131916.667+836%-859750.000+170%-2267650.000+284%
Usd Free Cash Flow Per Share--0.2790.288-3%0.123+128%0.030+836%-0.195+170%-0.261+193%
Usd Free Cash Flow To Equity Per Share---0.060-0.091+53%-0.179+199%-0.174+190%-0.263+338%-0.092+54%
Usd Market Cap3399031.510-22%4157707.4207273265.655-43%5099209.500-18%6982806.135-40%14583462.006-71%17892879.041-77%
Usd Price Per Share0.770-22%0.9401.647-43%1.155-19%1.582-41%3.303-72%2.328-60%
Usd Profit--1647000.0001970250.000-16%289750.000+468%-860000.000+152%-2277900.000+238%-2975425.000+281%
Usd Revenue--11515000.00012042000.000-4%10141250.000+14%10369250.000+11%9903150.000+16%6333350.000+82%
Usd Total Gains Per Share--0.3713.429-89%0.079+368%-0.052+114%-0.410+211%-0.029+108%
 EOD+3 -5MRQTTM+15 -18YOY+29 -53Y+29 -45Y+29 -510Y+28 -6

3.3 Fundamental Score

Let's check the fundamental score of Interpace Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.517
Price to Book Ratio (EOD)Between0-1-5.851
Net Profit Margin (MRQ)Greater than00.143
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.010
Current Ratio (MRQ)Greater than11.343
Debt to Asset Ratio (MRQ)Less than11.040
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.050.114
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of Interpace Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.794
Ma 20Greater thanMa 500.751
Ma 50Greater thanMa 1000.777
Ma 100Greater thanMa 2000.969
OpenGreater thanClose0.770
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Interpace Biosciences Inc

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier; and RespriDx, a genomic test that enables physicians to differentiate metastatic or recurrent lung cancer. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Fundamental data was last updated by Penke on 2025-06-30 02:19:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Interpace earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Interpace to theΒ Diagnostics & Research industry mean.
  • A Net Profit Margin of 14.3%Β means thatΒ $0.14 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Interpace Biosciences Inc:

  • The MRQ is 14.3%. The company is making a huge profit. +2
  • The TTM is 16.3%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ14.3%TTM16.3%-2.0%
TTM16.3%YOY2.6%+13.7%
TTM16.3%5Y-28.8%+45.1%
5Y-28.8%10Y-48.3%+19.5%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ14.3%-5.0%+19.3%
TTM16.3%-6.6%+22.9%
YOY2.6%-8.0%+10.6%
3Y-12.9%-8.5%-4.4%
5Y-28.8%-3.2%-25.6%
10Y-48.3%-1.0%-47.3%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Interpace is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Interpace to theΒ Diagnostics & Research industry mean.
  • 11.4% Return on Assets means thatΒ Interpace generatedΒ $0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Interpace Biosciences Inc:

  • The MRQ is 11.4%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 14.0%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ11.4%TTM14.0%-2.6%
TTM14.0%YOY2.4%+11.6%
TTM14.0%5Y-6.1%+20.1%
5Y-6.1%10Y-6.1%+0.0%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ11.4%-0.7%+12.1%
TTM14.0%-1.0%+15.0%
YOY2.4%-1.1%+3.5%
3Y-3.9%-1.1%-2.8%
5Y-6.1%--6.1%
10Y-6.1%0.3%-6.4%
4.3.1.3. Return on Equity

Shows how efficient Interpace is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Interpace to theΒ Diagnostics & Research industry mean.
  • 0.0% Return on Equity means Interpace generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Interpace Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-11.9%+11.9%
5Y-11.9%10Y-11.9%+0.0%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ--0.7%+0.7%
TTM--0.8%+0.8%
YOY--1.1%+1.1%
3Y--1.4%+1.4%
5Y-11.9%-1.0%-10.9%
10Y-11.9%-1.0%-10.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Interpace Biosciences Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Interpace is operatingΒ .

  • Measures how much profit Interpace makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Interpace to theΒ Diagnostics & Research industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Interpace Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY1.9%-1.9%
TTM-5Y-20.8%+20.8%
5Y-20.8%10Y-31.2%+10.4%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ--2.0%+2.0%
TTM--10.7%+10.7%
YOY1.9%-5.5%+7.4%
3Y-1.1%-0.1%-1.0%
5Y-20.8%4.0%-24.8%
10Y-31.2%4.5%-35.7%
4.3.2.2. Operating Ratio

Measures how efficient Interpace is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Diagnostics & Research industry mean).
  • An Operation Ratio of 1.20 means that the operating costs are $1.20 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Interpace Biosciences Inc:

  • The MRQ is 1.201. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.164. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.201TTM1.164+0.037
TTM1.164YOY1.327-0.162
TTM1.1645Y1.500-0.336
5Y1.50010Y1.546-0.046
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2011.420-0.219
TTM1.1641.302-0.138
YOY1.3271.292+0.035
3Y1.3531.284+0.069
5Y1.5001.259+0.241
10Y1.5461.189+0.357
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Interpace Biosciences Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Interpace is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Diagnostics & Research industry mean).
  • A Current Ratio of 1.34Β means the company has $1.34 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Interpace Biosciences Inc:

  • The MRQ is 1.343. The company is just able to pay all its short-term debts.
  • The TTM is 0.895. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ1.343TTM0.895+0.448
TTM0.895YOY0.823+0.072
TTM0.8955Y0.872+0.023
5Y0.87210Y1.163-0.291
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3432.072-0.729
TTM0.8952.087-1.192
YOY0.8232.424-1.601
3Y0.8412.472-1.631
5Y0.8722.618-1.746
10Y1.1633.175-2.012
4.4.3.2. Quick Ratio

Measures if Interpace is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Interpace to theΒ Diagnostics & Research industry mean.
  • A Quick Ratio of 1.01Β means the company can pay off $1.01 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Interpace Biosciences Inc:

  • The MRQ is 1.010. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 0.632. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ1.010TTM0.632+0.378
TTM0.632YOY0.377+0.256
TTM0.6325Y0.535+0.097
5Y0.53510Y0.901-0.366
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0101.085-0.075
TTM0.6321.146-0.514
YOY0.3771.371-0.994
3Y0.4501.598-1.148
5Y0.5351.843-1.308
10Y0.9012.228-1.327
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Interpace Biosciences Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of InterpaceΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Interpace to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 1.04Β means that Interpace assets areΒ financed with 104.0% credit (debt) and the remaining percentage (100% - 104.0%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Interpace Biosciences Inc:

  • The MRQ is 1.040. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 3.212. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.040TTM3.212-2.172
TTM3.212YOY5.393-2.180
TTM3.2125Y2.864+0.348
5Y2.86410Y1.705+1.159
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0400.385+0.655
TTM3.2120.426+2.786
YOY5.3930.385+5.008
3Y4.3070.387+3.920
5Y2.8640.407+2.457
10Y1.7050.446+1.259
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Interpace is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Interpace to theΒ Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Interpace Biosciences Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y1.446-1.446
5Y1.44610Y2.101-0.656
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.592-0.592
TTM-0.582-0.582
YOY-0.568-0.568
3Y-0.677-0.677
5Y1.4460.667+0.779
10Y2.1010.643+1.458
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Interpace generates.

  • Above 15 is considered overpriced butΒ always compareΒ Interpace to theΒ Diagnostics & Research industry mean.
  • A PE ratio of 0.63 means the investor is paying $0.63Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Interpace Biosciences Inc:

  • The EOD is 0.517. Based on the earnings, the company is cheap. +2
  • The MRQ is 0.631. Based on the earnings, the company is cheap. +2
  • The TTM is 0.957. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.517MRQ0.631-0.114
MRQ0.631TTM0.957-0.326
TTM0.957YOY2.231-1.274
TTM0.9575Y0.200+0.757
5Y0.20010Y-0.413+0.613
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD0.517-0.557+1.074
MRQ0.631-0.756+1.387
TTM0.957-0.557+1.514
YOY2.231-0.134+2.365
3Y1.491-0.087+1.578
5Y0.2005.675-5.475
10Y-0.4137.829-8.242
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Interpace Biosciences Inc:

  • The EOD is 0.689. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 0.842. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 1.491. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.689MRQ0.842-0.152
MRQ0.842TTM1.491-0.649
TTM1.491YOY-3.230+4.721
TTM1.4915Y-2.648+4.138
5Y-2.64810Y-2.196-0.452
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD0.689-0.842+1.531
MRQ0.842-1.081+1.923
TTM1.491-0.557+2.048
YOY-3.230-1.052-2.178
3Y-0.854-0.440-0.414
5Y-2.648-0.670-1.978
10Y-2.196-0.902-1.294
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Interpace is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Diagnostics & Research industry mean).
  • A PB ratio of -7.14 means the investor is paying $-7.14Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Interpace Biosciences Inc:

  • The EOD is -5.851. Based on the equity, the company is expensive. -2
  • The MRQ is -7.144. Based on the equity, the company is expensive. -2
  • The TTM is -3.185. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.851MRQ-7.144+1.293
MRQ-7.144TTM-3.185-3.959
TTM-3.185YOY-0.085-3.100
TTM-3.1855Y0.825-4.010
5Y0.82510Y0.912-0.088
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-5.8511.945-7.796
MRQ-7.1442.034-9.178
TTM-3.1852.143-5.328
YOY-0.0852.305-2.390
3Y-1.1422.491-3.633
5Y0.8253.533-2.708
10Y0.9124.485-3.573
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Interpace Biosciences Inc.

4.8.1. Institutions holding Interpace Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2020-12-31BlackRock Inc2.8485011715400
2020-12-31Geode Capital Management, LLC0.789603247600
2020-12-31Tower Research Capital LLC0.04690.0002192919290
2021-03-31Retirement Group, LLC0.02430.0023100010000
2020-12-31Advisor Group Holdings, Inc.0.001205000
2020-12-31Wells Fargo & Co0.000602500
2020-12-31Morgan Stanley - Brokerage Accounts0.00010300
2021-03-31Hanson Mcclain Inc000-1429-100
2021-03-31Dimensional Fund Advisors, Inc.000-12864-100
2021-03-31UBS Group AG000-2946-100
2020-12-31Citadel Advisors Llc000-11858-100
2020-12-31Magnus Financial Group LLC000-48500-100
2020-12-31Penbrook Management LLC000-84400-100
2020-12-31Stonepine Capital Management Llc000-284730-100
2021-03-31Vanguard Group Inc000-80612-100
2020-12-31Glenmede Trust Co NA000-797-100
2021-03-31Squarepoint Ops LLC000-20755-100
Total 3.71120.0025152637-545962-357.7%

4.9.2. Funds holding Interpace Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2021-03-31USAA Extended Market Index0.0120.0002494-142-22.327
2021-03-31NT Quality Small Cap Core0.000502200
2021-03-31NT Quality SCC US Fund - L0.000502200
2020-12-31NT Quality SCC Global Fund - NL00200
2020-12-31NT Quality SCC US Fund - NL00.0001200
Total 0.0130.0003542-142-26.2%

5.3. Insider Transactions

Insiders are holding 25.106% of the shares of Interpace Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-02-26Kamin PeterBUY163603.08270108
2021-02-26Kamin PeterBUY148743.17220079
2021-02-26Kamin PeterBUY147263.08234805
2021-02-26Kamin PeterBUY83333.17124934
2021-02-26Kamin PeterBUY82523.08133186
2021-02-26Kamin PeterBUY28973.1741808
2021-02-26Kamin PeterBUY28623.0844670
2021-02-26Kamin PeterBUY149463.17253748
2015-11-25Melillo Gerald R JrSELL17480.77130173
2015-11-25Melillo Gerald R JrSELL7650.8131921
2015-11-25Melillo Gerald R JrSELL42620.78132686
2014-11-24Miao Graham GBUY6001.6542499
2014-11-24Miao Graham GBUY214001.6563899
2014-11-07Melillo Gerald R JrBUY50001.5850224
2014-11-05Lurker NancyBUY275001.74460903
2014-11-05Lurker NancyBUY275001.75488403
2014-11-05Lurker NancyBUY5001.72488903
2014-11-05Lurker NancyBUY5001.72489403
2014-11-05Lurker NancyBUY10001.6490403
2013-11-15Belle Gerald P.BUY74005.1471357
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets14,494
Total Liabilities15,076
Total Stockholder Equity-582
 As reported
Total Liabilities 15,076
Total Stockholder Equity+ -582
Total Assets = 14,494

Assets

Total Assets14,494
Total Current Assets11,654
Long-term Assets2,840
Total Current Assets
Cash And Cash Equivalents 1,196
Net Receivables 8,768
Inventory 1,209
Other Current Assets 84
Total Current Assets  (as reported)11,654
Total Current Assets  (calculated)11,257
+/- 397
Long-term Assets
Property Plant Equipment 2,795
Long-term Assets Other 45
Long-term Assets  (as reported)2,840
Long-term Assets  (calculated)2,840
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,678
Long-term Liabilities6,398
Total Stockholder Equity-582
Total Current Liabilities
Short Long Term Debt 2,765
Accounts payable 1,733
Other Current Liabilities 660
Total Current Liabilities  (as reported)8,678
Total Current Liabilities  (calculated)5,158
+/- 3,520
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,474
Long-term Liabilities Other 5,318
Long-term Liabilities  (as reported)6,398
Long-term Liabilities  (calculated)6,792
+/- 394
Total Stockholder Equity
Total Stockholder Equity (as reported)-582
Total Stockholder Equity (calculated)0
+/- 582
Other
Capital Stock407
Common Stock Shares Outstanding 4,423
Net Debt 1,569
Net Invested Capital 2,183
Net Working Capital 2,976
Property Plant and Equipment Gross 2,795



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-31
> Total Assets 
160,551
170,377
174,744
270,225
306,192
312,487
298,451
302,671
266,068
198,210
198,473
190,939
185,499
186,577
198,409
219,623
227,261
223,380
218,861
224,705
216,656
218,998
216,678
200,306
200,743
200,790
200,429
201,636
190,085
185,345
179,429
179,554
171,911
166,296
156,805
149,036
133,433
125,692
124,925
109,776
106,320
112,586
114,839
124,389
121,711
116,951
124,212
113,379
108,935
104,819
106,079
78,447
82,797
77,277
73,214
69,064
65,382
59,459
62,227
115,906
112,612
107,573
99,287
67,712
56,775
53,510
45,964
41,778
46,975
53,744
50,391
53,598
53,097
51,356
49,801
48,442
54,382
50,332
74,673
51,540
60,775
60,611
50,701
50,701
43,858
43,185
40,307
38,427
38,358
35,488
15,293
15,979
15,877
15,942
14,250
13,116
12,142
12,972
14,039
14,792
14,494
14,49414,79214,03912,97212,14213,11614,25015,94215,87715,97915,29335,48838,35838,42740,30743,18543,85850,70150,70160,61160,77551,54074,67350,33254,38248,44249,80151,35653,09753,59850,39153,74446,97541,77845,96453,51056,77567,71299,287107,573112,612115,90662,22759,45965,38269,06473,21477,27782,79778,447106,079104,819108,935113,379124,212116,951121,711124,389114,839112,586106,320109,776124,925125,692133,433149,036156,805166,296171,911179,554179,429185,345190,085201,636200,429200,790200,743200,306216,678218,998216,656224,705218,861223,380227,261219,623198,409186,577185,499190,939198,473198,210266,068302,671298,451312,487306,192270,225174,744170,377160,551
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
75,113
82,849
80,360
76,450
72,854
75,458
71,583
76,657
70,797
66,524
62,709
59,009
53,176
42,206
44,866
43,062
39,291
32,099
19,165
11,674
9,639
6,683
4,240
10,659
18,337
15,773
19,808
20,140
19,205
18,245
17,721
22,233
19,153
20,581
16,510
28,145
26,096
17,632
17,632
14,265
14,638
13,083
12,166
13,118
11,258
12,739
12,154
12,484
12,975
11,438
10,417
9,416
10,166
11,110
11,773
11,654
11,65411,77311,11010,1669,41610,41711,43812,97512,48412,15412,73911,25813,11812,16613,08314,63814,26517,63217,63226,09628,14516,51020,58119,15322,23317,72118,24519,20520,14019,80815,77318,33710,6594,2406,6839,63911,67419,16532,09939,29143,06244,86642,20653,17659,00962,70966,52470,79776,65771,58375,45872,85476,45080,36082,84975,113000000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
109,000
0
0
0
160,043
0
0
0
66,827
0
0
0
113,288
0
0
0
96,367
0
0
0
90,827
0
0
0
45,221
54,866
90,800
110,822
99,185
101,525
95,964
94,310
90,074
80,931
76,202
70,551
72,463
72,691
80,891
83,355
62,711
64,329
64,020
65,451
64,337
61,872
56,938
60,529
52,783
53,333
51,023
49,627
45,639
37,878
35,621
27,005
23,111
17,004
14,397
8,955
8,310
4,340
3,039
1,693
602
7,126
14,265
11,703
15,199
12,645
10,084
8,002
6,068
9,124
4,210
2,358
2,321
13,370
15,106
5,308
5,308
3,439
3,791
3,180
3,064
2,850
1,865
6,309
4,828
5,596
5,079
5,032
3,498
2,812
2,019
2,113
1,461
1,196
1,1961,4612,1132,0192,8123,4985,0325,0795,5964,8286,3091,8652,8503,0643,1803,7913,4395,3085,30815,10613,3702,3212,3584,2109,1246,0688,00210,08412,64515,19911,70314,2657,1266021,6933,0394,3408,3108,95514,39717,00423,11127,00535,62137,87845,63949,62751,02353,33352,78360,52956,93861,87264,33765,45164,02064,32962,71183,35580,89172,69172,46370,55176,20280,93190,07494,31095,964101,52599,185110,82290,80054,86645,22100090,82700096,367000113,28800066,827000160,043000109,000000
       Short-term Investments 
0
0
0
4,907
0
0
0
7,387
0
0
0
5,834
0
0
0
1,344
0
0
0
13,131
0
0
0
6,807
0
0
0
69,463
66,410
20,477
6,383
7,800
9,557
6,662
5,616
159
146
195
196
3,822
2,543
2,856
601
227
635
124
127
127
121
91
90
92
92
92
96
103
103
103
105
107
108
108
108
106
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000001061081081081071051031031039692929290911211271271246352276012,8562,5433,8221961951461595,6166,6629,5577,8006,38320,47766,41069,4630006,80700013,1310001,3440005,8340007,3870004,907000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,708
13,735
12,226
10,384
11,121
9,250
12,642
16,615
13,657
10,665
10,404
14,029
10,782
9,741
14,423
18,884
18,152
17,524
2,806
2,780
2,950
2,753
2,209
2,265
2,696
2,803
3,437
6,403
7,647
8,640
9,483
11,221
12,966
14,701
10,338
9,799
7,239
8,463
8,463
7,851
7,327
6,518
6,158
7,241
6,446
4,792
5,032
4,715
5,529
4,830
5,078
5,006
6,206
7,293
8,544
8,768
8,7688,5447,2936,2065,0065,0784,8305,5294,7155,0324,7926,4467,2416,1586,5187,3277,8518,4638,4637,2399,79910,33814,70112,96611,2219,4838,6407,6476,4033,4372,8032,6962,2652,2092,7532,9502,7802,80617,52418,15218,88414,4239,74110,78214,02910,40410,66513,65716,61512,6429,25011,12110,38412,22613,7356,708000000000000000000000000000000000000000000000
       Inventory 
6,254
4,509
3,486
39,338
57,404
70,281
96,827
7,340
9,357
10,568
9,333
4,006
10,436
12,360
4,640
4,084
18,603
4,991
2,442
3,393
8,179
5,407
9,024
5,974
14,323
4,260
3,728
4,224
2,274
2,483
3,814
3,481
5,575
3,238
3,264
2,469
3,835
3,395
5,787
3,483
3,902
4,942
3,534
3,363
3,923
1,978
2,938
2,593
2,595
2,215
985
1,955
7,068
7,554
6,645
7,982
5,558
6,936
6,338
5,918
5,498
6,228
5,216
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,825
1,885
2,331
2,423
2,052
2,227
2,261
2,271
1,786
2,059
2,007
1,246
1,224
1,174
1,177
1,093
1,227
1,154
1,231
1,220
1,211
1,209
1,2091,2111,2201,2311,1541,2271,0931,1771,1741,2241,2462,0072,0591,7862,2712,2612,2272,0522,4232,3311,8851,82500000000000000005,2166,2285,4985,9186,3386,9365,5587,9826,6457,5547,0681,9559852,2152,5952,5932,9381,9783,9233,3633,5344,9423,9023,4835,7873,3953,8352,4693,2643,2385,5753,4813,8142,4832,2744,2243,7284,26014,3235,9749,0245,4078,1793,3932,4424,99118,6034,0844,64012,36010,4364,0069,33310,5689,3577,34096,82770,28157,40439,3383,4864,5096,254
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
41,838
41,363
33,019
32,485
31,965
30,621
6,864
6,140
6,480
6,690
6,355
6,373
6,283
20,021
71,040
69,550
68,282
67,188
48,547
45,101
43,871
39,281
37,538
36,316
35,407
34,618
33,790
32,957
32,151
31,556
30,721
27,509
31,179
54,092
35,030
32,630
34,515
33,069
33,069
29,593
28,547
27,224
26,261
25,240
24,230
2,554
3,825
3,393
2,967
2,812
2,699
2,726
2,806
2,929
3,019
2,840
2,8403,0192,9292,8062,7262,6992,8122,9673,3933,8252,55424,23025,24026,26127,22428,54729,59333,06933,06934,51532,63035,03054,09231,17927,50930,72131,55632,15132,95733,79034,61835,40736,31637,53839,28143,87145,10148,54767,18868,28269,55071,04020,0216,2836,3736,3556,6906,4806,1406,86430,62131,96532,48533,01941,36341,838000000000000000000000000000000000000000000000
       Property Plant Equipment 
4,185
4,858
6,109
9,965
11,240
14,332
18,013
21,044
22,132
22,152
19,951
18,295
17,266
16,369
15,809
14,494
15,724
16,892
18,369
17,170
17,788
16,217
15,591
16,053
15,214
14,594
13,809
12,809
12,096
10,754
9,722
8,348
7,504
6,634
5,985
5,423
4,949
3,814
3,355
3,530
3,342
3,391
3,030
4,047
3,608
3,267
2,881
2,484
2,218
2,387
2,199
2,396
2,553
2,775
3,122
2,789
2,846
2,812
2,945
3,184
3,323
3,083
2,818
1,460
1,330
1,190
1,060
929
770
644
668
654
634
640
859
837
758
731
7,033
6,814
6,610
7,249
7,332
7,332
6,900
6,930
10,473
10,381
9,905
9,453
1,295
2,919
2,804
2,696
2,740
2,654
2,681
2,761
2,884
2,974
2,795
2,7952,9742,8842,7612,6812,6542,7402,6962,8042,9191,2959,4539,90510,38110,4736,9306,9007,3327,3327,2496,6106,8147,0337317588378596406346546686447709291,0601,1901,3301,4602,8183,0833,3233,1842,9452,8122,8462,7893,1222,7752,5532,3962,1992,3872,2182,4842,8813,2673,6084,0473,0303,3913,3423,5303,3553,8144,9495,4235,9856,6347,5048,3489,72210,75412,09612,80913,80914,59415,21416,05315,59116,21717,78817,17018,36916,89215,72414,49415,80916,36917,26618,29519,95122,15222,13221,04418,01314,33211,2409,9656,1094,8584,185
       Goodwill 
0
0
0
4,300
0
0
0
0
11,000
9,600
11,100
11,132
11,132
11,132
11,132
11,132
11,132
11,132
21,759
23,791
23,820
23,744
24,244
13,112
13,112
13,612
13,612
13,612
13,612
13,612
13,612
13,612
13,612
13,612
13,612
13,612
13,612
13,612
13,612
5,068
5,068
5,068
5,068
23,876
23,976
23,976
23,976
18,908
18,908
18,908
18,908
2,523
2,523
2,523
2,523
2,523
2,523
2,523
2,523
15,545
15,545
15,666
15,666
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,273
8,433
8,433
8,433
8,433
8,433
8,433
8,433
8,433
8,433
8,433
8,433
0
0
0
0
0
0
0
0
0
0
0
000000000008,4338,4338,4338,4338,4338,4338,4338,4338,4338,4338,4338,27300000000000000015,66615,66615,54515,5452,5232,5232,5232,5232,5232,5232,5232,52318,90818,90818,90818,90823,97623,97623,97623,8765,0685,0685,0685,06813,61213,61213,61213,61213,61213,61213,61213,61213,61213,61213,61213,61213,61213,61213,11213,11224,24423,74423,82023,79121,75911,13211,13211,13211,13211,13211,13211,13211,1009,60011,00000004,300000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,057
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000001,05700000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
4,300
0
0
0
0
11,000
9,600
11,100
13,393
13,240
13,086
12,933
12,780
12,627
12,473
41,780
43,339
42,894
42,344
42,371
30,417
30,023
30,203
29,883
29,562
29,242
28,922
28,601
28,281
27,961
27,640
27,320
27,000
26,679
26,359
26,041
7,610
7,519
7,428
7,338
34,269
34,051
9,758
9,441
7,309
7,084
6,858
6,632
2,523
2,523
2,523
2,523
2,523
2,523
2,523
13,459
47,304
46,434
45,448
44,478
43,492
42,522
41,553
37,220
36,358
35,545
34,732
33,919
33,105
32,292
31,480
30,666
29,853
29,040
28,227
34,532
15,849
14,734
13,619
12,504
12,504
10,238
9,126
8,014
7,287
6,751
6,215
1,179
861
544
226
27
0
0
0
0
0
0
000000272265448611,1796,2156,7517,2878,0149,12610,23812,50412,50413,61914,73415,84934,53228,22729,04029,85330,66631,48032,29233,10533,91934,73235,54536,35837,22041,55342,52243,49244,47845,44846,43447,30413,4592,5232,5232,5232,5232,5232,5232,5236,6326,8587,0847,3099,4419,75834,05134,2697,3387,4287,5197,61026,04126,35926,67927,00027,32027,64027,96128,28128,60128,92229,24229,56229,88330,20330,02330,41742,37142,34442,89443,33941,78012,47312,62712,78012,93313,08613,24013,39311,1009,60011,00000004,300000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,837
5,065
4,318
4,275
3,812
2,882
1,945
1,064
1,182
1,045
1,043
1,004
948
1,094
5,007
4,248
4,085
4,226
3,595
1,249
1,128
1,001
251
1
31
31
31
31
31
31
31
-2,289
2,221
4,254
3,934
2,853
5,214
4,800
4,800
4,022
4,058
304
160
151
129
80
45
45
45
45
45
45
45
45
45
45
45454545454545454545801291511603044,0584,0224,8004,8005,2142,8533,9344,2542,221-2,2893131313131313112511,0011,1281,2493,5954,2264,0854,2485,0071,0949481,0041,0431,0451,1821,0641,9452,8823,8124,2754,3185,0654,837000000000000000000000000000000000000000000000
> Total Liabilities 
51,033
55,504
53,741
132,115
156,928
158,240
161,395
151,736
117,240
56,784
71,300
67,728
61,368
58,523
65,808
81,135
81,594
69,932
59,594
59,280
50,686
54,375
61,699
64,696
59,222
57,784
56,309
52,439
42,465
40,099
37,971
39,365
32,488
33,853
33,236
41,929
31,576
28,257
31,781
34,886
32,790
39,522
43,143
54,876
52,027
47,631
54,671
53,856
49,365
45,082
46,894
42,817
44,917
39,562
37,207
36,585
34,040
30,107
36,803
95,784
95,988
97,275
93,426
54,674
48,469
47,517
47,443
35,247
22,406
17,402
14,013
13,729
13,332
12,804
13,772
15,504
18,611
19,503
37,915
29,847
25,137
30,202
25,963
25,963
30,218
32,440
32,419
34,309
36,163
83,440
76,886
79,051
78,415
78,148
76,930
68,655
73,283
71,998
71,721
17,009
15,076
15,07617,00971,72171,99873,28368,65576,93078,14878,41579,05176,88683,44036,16334,30932,41932,44030,21825,96325,96330,20225,13729,84737,91519,50318,61115,50413,77212,80413,33213,72914,01317,40222,40635,24747,44347,51748,46954,67493,42697,27595,98895,78436,80330,10734,04036,58537,20739,56244,91742,81746,89445,08249,36553,85654,67147,63152,02754,87643,14339,52232,79034,88631,78128,25731,57641,92933,23633,85332,48839,36537,97140,09942,46552,43956,30957,78459,22264,69661,69954,37550,68659,28059,59469,93281,59481,13565,80858,52361,36867,72871,30056,784117,240151,736161,395158,240156,928132,11553,74155,50451,033
   > Total Current Liabilities 
50,202
54,673
52,906
131,283
156,096
157,408
160,563
151,436
116,940
56,484
70,350
67,728
61,368
58,523
65,808
81,135
81,594
69,932
59,594
59,280
50,686
54,375
61,016
64,696
59,222
57,784
56,309
44,554
34,256
32,479
30,397
29,188
22,207
23,734
22,652
31,360
20,912
16,867
20,107
24,880
23,205
29,640
33,361
43,328
42,053
38,283
45,147
46,078
42,162
38,375
40,350
36,390
38,725
33,783
31,626
31,400
29,304
25,621
28,667
33,578
33,998
34,931
31,526
23,373
19,746
19,209
19,870
16,241
13,024
10,855
8,302
8,091
7,794
7,354
7,762
8,492
9,832
10,966
17,296
17,292
15,726
16,098
15,601
15,601
20,461
22,814
22,836
15,682
16,870
18,449
14,810
14,283
13,851
13,565
12,324
11,436
18,973
19,030
18,769
10,615
8,678
8,67810,61518,76919,03018,97311,43612,32413,56513,85114,28314,81018,44916,87015,68222,83622,81420,46115,60115,60116,09815,72617,29217,29610,9669,8328,4927,7627,3547,7948,0918,30210,85513,02416,24119,87019,20919,74623,37331,52634,93133,99833,57828,66725,62129,30431,40031,62633,78338,72536,39040,35038,37542,16246,07845,14738,28342,05343,32833,36129,64023,20524,88020,10716,86720,91231,36022,65223,73422,20729,18830,39732,47934,25644,55456,30957,78459,22264,69661,01654,37550,68659,28059,59469,93281,59481,13565,80858,52361,36867,72870,35056,484116,940151,436160,563157,408156,096131,28352,90654,67350,202
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,154
0
0
0
1,164
2,463
3,755
3,756
7,908
4,364
0
0
0
0
0
0
0
526
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000052600000004,3647,9083,7563,7552,4631,16400027,15400000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,154
0
0
0
1,164
0
0
0
7,908
4,364
0
0
0
0
0
0
0
526
0
0
0
0
0
0
0
5,092
7,720
7,872
0
0
2,000
2,500
2,500
2,200
1,500
0
5,100
7,498
6,784
5,688
4,290
2,765
2,7654,2905,6886,7847,4985,10001,5002,2002,5002,5002,000007,8727,7205,092000000052600000004,3647,9080001,16400027,15400000000000000000000000000000000000000000000000000000000000
       Accounts payable 
10,186
5,684
3,559
31,328
48,953
42,921
38,404
9,493
5,862
5,119
4,685
5,374
5,011
5,484
5,164
8,689
8,717
5,162
3,394
7,217
4,805
4,213
4,193
5,693
2,869
2,442
2,878
3,915
1,880
1,987
1,524
2,792
1,456
2,203
2,628
2,298
798
1,588
1,573
1,994
3,676
731
2,171
3,266
2,789
23,017
23,764
30,196
25,607
21,959
24,100
21,889
24,850
21,814
19,608
22,021
20,519
17,770
21,056
26,826
23,102
28,061
26,414
9,945
10,769
10,208
11,359
12,113
10,278
8,484
7,019
6,789
6,809
6,415
6,863
7,574
8,914
10,200
16,530
16,526
14,960
15,332
14,835
14,835
19,695
22,048
2,427
2,694
3,951
3,522
1,446
1,050
1,582
1,689
1,352
1,544
1,363
1,761
1,701
1,659
1,733
1,7331,6591,7011,7611,3631,5441,3521,6891,5821,0501,4463,5223,9512,6942,42722,04819,69514,83514,83515,33214,96016,52616,53010,2008,9147,5746,8636,4156,8096,7897,0198,48410,27812,11311,35910,20810,7699,94526,41428,06123,10226,82621,05617,77020,51922,02119,60821,81424,85021,88924,10021,95925,60730,19623,76423,0172,7893,2662,1717313,6761,9941,5731,5887982,2982,6282,2031,4562,7921,5241,9871,8803,9152,8782,4422,8695,6934,1934,2134,8057,2173,3945,1628,7178,6895,1645,4845,0115,3744,6855,1195,8629,49338,40442,92148,95331,3283,5595,68410,186
       Other Current Liabilities 
40,016
48,989
49,347
99,955
107,143
114,487
122,159
141,943
111,078
51,365
65,665
62,354
56,357
53,039
60,644
72,446
72,877
64,770
56,200
52,063
45,881
50,162
52,389
52,198
49,174
47,974
45,691
38,878
30,611
28,354
26,329
26,396
20,751
21,531
20,024
29,062
20,114
15,279
18,534
22,886
19,529
28,909
31,190
40,062
39,264
15,266
21,383
15,882
16,555
16,416
16,250
14,501
13,875
11,969
12,018
9,379
8,785
7,851
7,611
6,752
10,896
6,870
5,112
12,264
30,541
5,246
9,370
11,382
6,438
7,552
5,837
5,591
985
939
899
918
918
766
766
766
766
766
766
766
766
766
2,092
2,175
2,127
2,090
2,017
858
858
1,951
858
660
660
660
660
660
660
6606606606606606608581,9518588582,0172,0902,1272,1752,0927667667667667667667667667669189188999399855,5915,8377,5526,43811,3829,3705,24630,54112,2645,1126,87010,8966,7527,6117,8518,7859,37912,01811,96913,87514,50116,25016,41616,55515,88221,38315,26639,26440,06231,19028,90919,52922,88618,53415,27920,11429,06220,02421,53120,75126,39626,32928,35430,61138,87845,69147,97449,17452,19852,38950,16245,88152,06356,20064,77072,87772,44660,64453,03956,35762,35465,66551,365111,078141,943122,159114,487107,14399,95549,34748,98940,016
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,348
9,524
7,778
7,203
6,707
6,544
6,427
6,192
5,779
5,581
5,185
4,736
4,486
8,136
9,143
8,732
8,741
8,080
6,178
4,696
28,308
22,958
11,752
5,690
1,366
1,157
1,349
4,266
4,339
4,730
4,319
4,253
8,537
20,619
12,555
9,411
14,104
10,362
10,362
9,757
9,626
9,583
18,627
19,293
64,991
62,076
64,768
64,564
64,583
64,606
57,219
54,310
52,968
52,952
6,394
6,398
6,3986,39452,95252,96854,31057,21964,60664,58364,56464,76862,07664,99119,29318,6279,5839,6269,75710,36210,36214,1049,41112,55520,6198,5374,2534,3194,7304,3394,2661,3491,1571,3665,69011,75222,95828,3084,6966,1788,0808,7418,7329,1438,1364,4864,7365,1855,5815,7796,1926,4276,5446,7077,2037,7789,5249,348000000000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,154
27,349
27,694
27,911
7,233
0
5,055
5,267
7,908
4,364
0
0
0
0
0
0
0
0
0
3,750
3,000
1,200
3,400
0
3,400
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000003,40003,4001,2003,0003,7500000000004,3647,9085,2675,05507,23327,91127,69427,34927,15400000000000000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-27,154
0
0
0
-1,164
-2,463
-3,755
-3,756
-7,908
-4,364
0
0
0
0
0
0
0
1,899
2,312
4,158
4,096
2,795
5,261
4,990
4,744
4,370
4,124
4,355
4,274
3,997
3,722
852
2,426
2,290
2,089
1,970
1,849
1,734
1,605
1,494
1,566
1,474
1,4741,5661,4941,6051,7341,8491,9702,0892,2902,4268523,7223,9974,2744,3554,1244,3704,7444,9905,2612,7954,0964,1582,3121,8990000000-4,364-7,908-3,756-3,755-2,463-1,164000-27,15400000000000000000000000000000000000000000000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,161
26,172
46,536
46,536
46,536
46,536
46,536
46,536
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000046,53646,53646,53646,53646,53646,53626,17213,161000000000000000000000000000000000000000000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,778
0
0
0
0
0
0
0
0
0
0
0
25,909
25,909
25,909
25,909
17,890
4,696
23,253
17,691
3,844
1,326
1,366
1,157
1,349
1,272
1,111
1,280
2,693
4,526
8,537
16,869
9,555
8,211
10,704
10,362
10,362
9,757
9,626
6,180
6,018
6,017
5,469
5,368
5,219
5,148
5,094
4,949
4,968
5,072
5,146
5,227
5,211
5,318
5,3185,2115,2275,1465,0724,9684,9495,0945,1485,2195,3685,4696,0176,0186,1809,6269,75710,36210,36210,7048,2119,55516,8698,5374,5262,6931,2801,1111,2721,3491,1571,3661,3263,84417,69123,2534,69617,89025,90925,90925,90925,909000000000007,77800000000000000000000000000000000000000000000000
> Total Stockholder Equity
109,518
114,873
121,003
138,110
149,264
154,247
137,056
150,935
148,828
141,426
127,173
123,211
124,131
128,054
132,601
138,488
145,667
153,448
159,267
165,425
165,970
164,623
154,979
135,610
141,521
143,006
144,120
149,197
147,620
145,246
141,458
140,189
139,423
132,443
123,569
107,107
101,857
97,435
93,144
74,890
73,530
73,064
71,696
69,513
69,684
69,320
69,541
59,523
59,570
59,737
59,185
35,630
37,880
37,715
36,007
32,479
31,342
29,352
25,424
20,122
16,624
10,298
5,861
13,038
8,306
5,993
-1,479
6,531
24,569
36,342
36,378
39,869
39,765
38,552
36,029
32,938
35,771
30,829
23,597
-4,479
-10,898
-16,127
-21,798
-21,798
-32,896
-35,791
7,888
4,118
2,195
-47,952
-61,593
-63,072
-62,538
-62,206
-62,680
-55,539
-61,141
-59,026
-57,682
-2,217
-582
-582-2,217-57,682-59,026-61,141-55,539-62,680-62,206-62,538-63,072-61,593-47,9522,1954,1187,888-35,791-32,896-21,798-21,798-16,127-10,898-4,47923,59730,82935,77132,93836,02938,55239,76539,86936,37836,34224,5696,531-1,4795,9938,30613,0385,86110,29816,62420,12225,42429,35231,34232,47936,00737,71537,88035,63059,18559,73759,57059,52369,54169,32069,68469,51371,69673,06473,53074,89093,14497,435101,857107,107123,569132,443139,423140,189141,458145,246147,620149,197144,120143,006141,521135,610154,979164,623165,970165,425159,267153,448145,667138,488132,601128,054124,131123,211127,173141,426148,828150,935137,056154,247149,264138,110121,003114,873109,518
   Common Stock
136
136
137
138
138
139
139
140
140
141
141
142
142
144
144
145
147
148
148
148
148
149
149
149
151
151
151
151
152
152
152
152
153
153
152
153
153
153
153
153
153
154
154
155
157
158
158
158
160
160
160
161
161
163
163
163
165
165
165
165
174
174
174
187
187
187
187
22
68
201
230
278
279
282
283
287
382
383
383
393
402
402
402
402
402
402
403
403
404
404
404
405
0
405
0
0
0
0
0
0
0
000000040504054044044044034034024024024024024023933833833822872832822792782302016822187187187187174174174165165165165163163163161161160160160158158158157155154154153153153153153153152153153152152152152151151151151149149149148148148148147145144144142142141141140140139139138138137136136
   Retained Earnings 
20,240
25,078
30,786
41,620
52,492
56,922
39,610
47,929
45,693
36,462
22,095
17,147
17,956
20,859
25,062
29,530
35,534
40,581
46,037
50,713
50,600
55,213
51,085
31,254
36,888
37,762
38,233
43,071
41,164
38,682
34,638
33,048
31,957
24,480
15,470
0
0
0
0
0
0
0
0
0
0
-43,262
-43,465
-53,731
-54,003
-54,442
-55,462
-79,258
-77,132
-78,016
-80,157
-83,823
-85,435
-88,093
-92,428
-99,896
-103,764
-110,742
-115,637
-111,252
-116,038
-118,372
-125,865
-119,584
-117,170
-123,476
-126,792
-131,800
-132,493
-134,410
-137,452
-141,489
-144,853
-150,073
-157,435
-185,665
-192,159
-197,739
-203,973
-203,973
-216,323
-219,769
-223,330
-227,059
-229,306
-233,245
-247,453
-249,017
-248,666
-248,491
-249,105
-242,082
-247,747
-245,685
-244,405
-235,380
-233,733
-233,733-235,380-244,405-245,685-247,747-242,082-249,105-248,491-248,666-249,017-247,453-233,245-229,306-227,059-223,330-219,769-216,323-203,973-203,973-197,739-192,159-185,665-157,435-150,073-144,853-141,489-137,452-134,410-132,493-131,800-126,792-123,476-117,170-119,584-125,865-118,372-116,038-111,252-115,637-110,742-103,764-99,896-92,428-88,093-85,435-83,823-80,157-78,016-77,132-79,258-55,462-54,442-54,003-53,731-43,465-43,262000000000015,47024,48031,95733,04834,63838,68241,16443,07138,23337,76236,88831,25451,08555,21350,60050,71346,03740,58135,53429,53025,06220,85917,95617,14722,09536,46245,69347,92939,61056,92252,49241,62030,78625,07820,240
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
126,043
126,467
126,720
127,147
127,754
128,238
128,508
128,859
129,579
130,025
130,229
130,917
131,585
131,991
134,171
134,558
129,106
129,569
132,522
125,800
125,821
125,842
127,736
143,342
161,288
164,611
173,062
173,659
174,360
174,878
175,820
181,954
182,231
182,361
182,514
182,580
182,980
183,543
183,543
184,798
185,349
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000185,349184,798183,543183,543182,980182,580182,514182,361182,231181,954175,820174,878174,360173,659173,062164,611161,288143,342127,736125,842125,821125,800132,522129,569129,106134,558134,171131,991131,585130,917130,229130,025129,579128,859128,508128,238127,754127,147126,720126,467126,043000000000000000000000000000000000000000000000
   Treasury Stock000000000000000-1,773-1,773-1,770-1,770-1,770-1,721-1,721-1,712-1,712-1,712-1,680-1,680-1,680-1,680-1,671-1,671-1,671-1,671-1,643-1,643-1,643-1,643-8,432-8,261-8,256-14,360-14,334-14,321-14,321-14,321-14,106-14,037-14,022-14,019-13,792-13,761-13,746-13,741-13,636-13,631-13,629-13,629-13,620-13,595-13,582-13,580-13,558-13,554-13,546-13,518-13,495-13,479-13,433-13,433-13,433-13,421-13,352-13,214-13,214-13,214-13,214-13,214-13,214-12,973-7,154-110-110-110-110-110-110-110-110-110-110-110-110-110-1100000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
12
12
7
11
10
11
11
11
13
16
16
16
17
16
16
16
16
13
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000001316161616171616161311111110117121210000000000000000000000000000000000000000000000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue46,926
Cost of Revenue-17,001
Gross Profit29,92529,925
 
Operating Income (+$)
Gross Profit29,925
Operating Expense-38,818
Operating Income8,108-8,893
 
Operating Expense (+$)
Research Development676
Selling General Administrative21,141
Selling And Marketing Expenses0
Operating Expense38,81821,817
 
Net Interest Income (+$)
Interest Income0
Interest Expense-659
Other Finance Cost-0
Net Interest Income-659
 
Pretax Income (+$)
Operating Income8,108
Net Interest Income-659
Other Non-Operating Income Expenses0
Income Before Tax (EBT)6,9508,607
EBIT - interestExpense = -659
6,702
7,361
Interest Expense659
Earnings Before Interest and Taxes (EBIT)07,609
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax6,950
Tax Provision-4
Net Income From Continuing Ops6,9466,946
Net Income6,702
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-499659
 

Technical Analysis of Interpace
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Interpace. The general trend of Interpace is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Interpace's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Interpace Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Interpace Biosciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.777 < 0.91 < 0.92.

The bearish price targets are: 0.7 > 0.7 > 0.7.

Know someone who trades $IDXG? Share this with them.πŸ‘‡

Interpace Biosciences Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Interpace Biosciences Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Interpace Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Interpace Biosciences Inc. The current macd is -0.01770171.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Interpace price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Interpace. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Interpace price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Interpace Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartInterpace Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Interpace Biosciences Inc. The current adx is 17.85.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Interpace shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Interpace Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Interpace Biosciences Inc. The current sar is 0.60446254.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Interpace Biosciences Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Interpace Biosciences Inc. The current rsi is 49.79. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Interpace Biosciences Inc Daily Relative Strength Index (RSI) ChartInterpace Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Interpace Biosciences Inc. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Interpace price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Interpace Biosciences Inc Daily Stochastic Oscillator ChartInterpace Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Interpace Biosciences Inc. The current cci is 55.10.

Interpace Biosciences Inc Daily Commodity Channel Index (CCI) ChartInterpace Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Interpace Biosciences Inc. The current cmo is 7.55433247.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Interpace Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartInterpace Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Interpace Biosciences Inc. The current willr is -0.14285714.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Interpace Biosciences Inc Daily Williams %R ChartInterpace Biosciences Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Interpace Biosciences Inc.

Interpace Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Interpace Biosciences Inc. The current atr is 0.03881035.

Interpace Biosciences Inc Daily Average True Range (ATR) ChartInterpace Biosciences Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Interpace Biosciences Inc. The current obv is -156,390.

Interpace Biosciences Inc Daily On-Balance Volume (OBV) ChartInterpace Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Interpace Biosciences Inc. The current mfi is 64.55.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Interpace Biosciences Inc Daily Money Flow Index (MFI) ChartInterpace Biosciences Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Interpace Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-04-02ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-03RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-04MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-07STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-14STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-07STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-08MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-07-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Interpace Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Interpace Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.794
Ma 20Greater thanMa 500.751
Ma 50Greater thanMa 1000.777
Ma 100Greater thanMa 2000.969
OpenGreater thanClose0.770
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Interpace with someone you think should read this too:
  • Are you bullish or bearish on Interpace? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Interpace? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Interpace Biosciences Inc

I send you an email if I find something interesting about Interpace Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Interpace Biosciences Inc.

Receive notifications about Interpace Biosciences Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.